Drug Combo Proves Powerful Against Lung Cancer Massapequa NY

A two-drug combination treatment in Massapequa proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
MARK ATLAS, MD
(718) 470-3470
Schneider Children'S Hospital
New Hyde Park, NY
LEONARD JAMES, MD
(718) 460-2300
176-60 Union Turnpike
Fresh Meadows, NY
Vijaykumar Ratanlal Shah, MD
2201 Hempstead Tpke
East Meadow, NY
David L Benninghoff, MD
516-351-2295
270 Park Ave
Huntington, NY
Rita Weiss
(516) 482-0080
107 Northern Blvd
Great Neck, NY
BER-YUH YANG, MD
(718) 539-8483
13511 40Th Road
Flushing, NY
MRUDULA SHAH, MD
(516) 822-4706
528 Old Country Road
Plainview, NY
Jatinder B S Khokhar, MD
Valley Stream, NY
Milton Ronald Beyers, MD
516-669-3688
74 Boathouse Ln
Bay Shore, NY
Data Provided by:
      

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Side Effect Of Chemotherapy Drugs Massapequa NY
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin. Read on and learn more.
- Genetic Clues for Skin Cancer Therapies Massapequa NY
- Exercise for Prostate Cancer Massapequa NY
- Delayed Prostate Cancer Therapy Massapequa NY
- Hormone Therapy for Lung Cancer Massapequa NY
- Risks for Childhood Cancer Survivors Massapequa NY
- Exercise for Breast Cancer Survival Massapequa NY
- Hormone Therapy for Breast Cancer Massapequa NY
- Fungal Infection Treatments Massapequa NY